All In Biotech

Drug Trial Radar · NCT07648030

A Study of Rusfertide in Japanese Adults With Polycythemia Vera

A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients With Polycythemia Vera

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Jul 14, 2026

Primary completion

Oct 28, 2027

Study completion May 17, 2030

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots. Many people with PV need regular phlebotomy, which is a procedure to remove blood, to help keep their hematocrit level under control. Hematocrit is the proportion of red blood cells in the blood. The main aim of this study is to evaluate whether rusfertide helps Japanese participants with PV keep their hematocrit under control and avoid the need for phlebotomy. All participants in this study will receive rusfertide. This study is open-label, which means both the participants and the study team will know what treatment is being given. Participants will be followed for up to about 244 weeks, including a screening period, a 52-week initial treatment period, a long-term extension period, and a 4-week safety follow-up period.

Conditions

  • Polycythemia Vera

Interventions

  • RusfertideDrug

    Rusfertide injections administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving a Response Starting at Week 20 through Week 32Time frame: Week 20, up to Week 32

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miyazaki Hospital

    Miyazaki, Japan · Recruiting

  • Nagoya Medical Center

    Nagoya, Aichi-ken, Japan · Recruiting

  • Gunma University Hospital

    Maebashi, Gunma, Japan · Not yet recruiting

  • Mie University Hospital

    Tsu, Mie-ken, Japan · Recruiting

  • University of Osaka Hospital

    Suita, Osaka, Japan · Recruiting

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Tokyo Metropilitan Bokutoh Hospital

    Sumida-ku, Tokyo, Japan · Recruiting

  • University of Yamanashi Hospital

    Chūō, Yamanashi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.